A Randomised, Double-blinded, Single-dose, Dose-escalation, First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Trial Profile

A Randomised, Double-blinded, Single-dose, Dose-escalation, First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs NNC0194 0499 (Primary)
  • Indications Obesity
  • Focus Adverse reactions; First in man
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 26 Sep 2017 Planned primary completion date changed from 2 Oct 2017 to 26 Oct 2017.
    • 26 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 Jul 2017 Planned End Date changed from 2 Oct 2017 to 26 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top